Treatment of hormone-refractory prostate cancer, HRPC, remains challenging. In the journal Medical Oncology, we read with interest the article written by Nelius et al. [1] in which they concluded metronomic cyclophosphamide may be beneficial for patients with docetaxel-resistant HRPC. In this pilot...
New progress in treatment of hormone-refractory prostate cancer : The Lancet Oncologydoi:10.1016/S1470-2045(04)01641-9KhabirAhmadSDOSLancet OncologyAhmad K: New progress in treatment of hormone-refractory prostate cancer. Lancet Oncol 5: 706, 2004....
Conclusions: The combination of ketoconazole, hydrocortisone, and cyclophosphamide is a well-tolerated oral regimen for the treatment of patients with metastatic hormone-refractory prostate cancer with significant disease activity, and it warrants further investigation....
We refer to this state of the disease as castration-resistant prostate cancer (CRPC). Because most of these tumours still depend on androgen-receptor signalling for growth, the terms androgen-independent or hormone-refractory are not appropriate.3 Only one treatment, docetaxel, is approved by the...
Hormone-refractory prostate cancer (HRCaP) is both heterogeneous and lethal. Multiple treatment options exist, including secondary hormonal manipulations, chemotherapy, experimental options, and best supportive care. Choosing the appropriate therapy for an individual patient depends on several ...
这是被批准用于治疗激素抵抗性前列腺癌(hormone refractory prostate cancer)的首个药物。该药已显示出有促进患者生存的 … www.oneyao.net|基于10个网页 2. 激素非依赖性前列腺癌 ... )hormone refractory prostate cancer激素非依赖性前列腺癌) androgen-dependence prostate cancer 雄激素依赖性前列腺癌 ... ...
Evaluation and incorporation of these agents into existing treatment regimens will guide us in the development of more active regimens in the treatment of HRPC. 展开 关键词: hormone-refractory prostate cancer treatment resistance taxanes DOI: 10.1634/theoncologist.7-4-360 ...
Hormone-refractory prostate cancer (HRPC) encompasses a wide spectrum of patients, including patients with prostate-specific antigen (PSA)–only disease, those with increasing PSA levels yet stable metastatic disease, and those with increasing PSA levels and objective evidence of progressive metastases. ...
Prostate CancerIntermittent ChemotherapyHormone Refractory Prostate CancerIntroduction: Prostate cancer is one of the most common cancers among males and the second factor resulting to death due to cancer among them.(1) The median age of its diagnosis is 65 years. The initial treatment includes ...
In conclusion, there have been impressive efforts to identify new cellular targets for the treatment of hormone-refractory disease. It appears that in some cases, survival may be extended; however, further prospective trials are necessary to confirm these observations.DOI...